Published in AIDS Weekly, March 19th, 2001
R.E. Polk and colleagues at Virginia Commonwealth University studied the interactions between amprenavir and common prophylactic MAC treatments.
They found that amprenavir can prevent the clearance of rifabutin, forcing almost half of the patients studied to discontinue therapy. Conversely, rifampin was found to hasten amprenavir clearance.
Concomitant administration of amprenavir and rifabutin increased...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.